CEO Ron Cooper said the company’s focus is advancing its DDX platform, a proprietary non-viral gene therapy technology, with its lead program detalimogene being developed for non-muscle invasive ...
Dr. Aleksander Słusarczyk presented the clinical case of a 75-year-old woman who presented with a two-month history of hematuria. Her medical history was notable for diabetes, prior myocardial ...
Bladder cancer is often discovered because a person notices blood in their urine. For many patients, this is the first warning sign that something is wrong. Seeing this change usually encourages ...
Over a median follow-up in responders of 18.0 months (range 15-21), the median duration of complete response was 18.0 months ...
A prospective, multicenter phase 2 trial evaluated the safety of neoadjuvant radiation plus immunotherapy before radical cystectomy for bladder cancer.
National survey of more than 1,100 bladder cancer patients finds nearly 80% report fear of recurrence, rising above 90% among patients under 50; Many respondents report undergoing ...
A new national survey from the Bladder Cancer Advocacy Network (BCAN) finds that many bladder cancer patients still face major gaps in diagnosis, mental health support and financial protection, ...
(Combat), a medical device company optimizing the delivery and efficacy of cancer therapeutics, today announced it has raised £2.6 million in the first close of a Series A financing to advance its ...
Brian Holmes is the first man in the UK and only the fifth in the world to take part in the clinical trial [BBC] A prostate cancer patient hopes a new treatment can help prolong the lives of thousands ...
The MarketWatch News Department was not involved in the creation of this content. -- Investment led by T&J Meyer Family Foundation, joined by Varia Ventures, NW Angel Fund and other non-institutional ...
KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results